معرفی
Peter Gennemark is an Adjunct Associate Professor and Docent at the Department of Biomedical Engineering (IMT), Division of Biomedical Engineering (MT), Linköping University, with a strong collaborative role in systems pharmacology. He is also a Principal Scientist at AstraZeneca, Gothenburg, Sweden, where he contributes to industrial pharmaceutical research. His academic and industrial work is centered on mathematical modelling to understand diabetes and cardiovascular disease mechanisms and therapies.
- Institution: Linköping University
- Department: Department of Biomedical Engineering (IMT)
- Division: Division of Biomedical Engineering (MT)
- Industry Role: Principal Scientist, AstraZeneca
- Collaborator: Gunnar Cedersund (IMT)
His research lies at the intersection of biomedical engineering and systems pharmacology, focusing on mathematical modelling to unravel biological mechanisms in diabetes and cardiovascular diseases. He contributes to knowledge-driven drug development, particularly in understanding disease progression and drug intervention effects. His work combines experimental data with computational models to support clinical tool and drug development.
The recent publications (2024–2025) demonstrate a strong trend in systems pharmacology, drug delivery, and microphysiological systems. Topics include siRNA delivery, antisense oligonucleotide pharmacokinetics, 3D cell models, glucose homeostasis, and liver steatosis dynamics. These works reflect a consistent focus on quantitative, model-driven approaches in drug development and disease understanding, spanning molecular, cellular, and organ-level systems.
Peter Gennemark is involved in a VR Medicine-funded project on Knowledge Driven Drug Development in collaboration with AstraZeneca. While no specific grants or students are listed, his role as a principal scientist and adjunct faculty suggests active involvement in research leadership and interdisciplinary advising. His work bridges academia and industry, contributing to both scientific advancement and pharmaceutical innovation.
His research is conducted within the Division of Biomedical Engineering at Linköping University, a national hub for biomedical research and education. He is part of a collaborative team working on systems biology and pharmacological modelling, particularly with Gunnar Cedersund. The lab environment emphasizes interdisciplinary integration of mathematical models, biological data, and pharmaceutical applications.
